查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771483

美国主髂动脉阻塞性疾病治疗市场：市场规模、份额、趋势分析（按设备类型、程序和最终用途）、细分市场预测（2025-2030 年）

U.S. Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Report By Device Type, By Procedure, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场规模预计在2024年达到7.166亿美元，预计2025年至2030年的复合年增长率为5.4%。週边动脉疾病（PAD）盛行率的上升、政府相关倡议的不断增加以及技术的进步正在推动市场成长。例如，飞利浦于2024年11月在美国启动了THOR IDE临床试验，以评估一种结合雷射动脉粥状硬化斑块切除术和血管内碎石术的新型混合导管系统。

该设备用于治疗週边动脉疾病 (PAD) 和主髂动脉疾病中常见的严重钙化病变。路易斯安那州南方心血管研究所首次成功实施的患者手术证明了该设备在简化复杂干预措施和改善手术结果方面的潜力。越来越多的政府倡议推动市场成长 根据 2023 年 6 月发表的一篇 Congress.Gov报导，美国政府透过推出《综合动脉和静脉 (ARC) 法案》，在加强周边动脉疾病(PAD)（主髂动脉阻塞性疾病的主要原因）的早期发现和管理方面迈出了重要一步。该立法提案对《社会保障法》进行修订，旨在允许被确定为高风险的医疗保险和医疗补助受益人免费接受 PAD 筛检。

有针对性的诊断方法包括踝臂指数 (ABI) 测试和动脉双功能扫描，这些方法对于识别週边动脉疾病 (PAD) 和评估主髂动脉区域的疾病严重程度至关重要。 ARC 法案授权在 2024 年至 2028 年期间每年拨款 600 万美元，旨在探索改善早期诊断和及时干预、减轻晚期阻塞性疾病负担以及增加对髂动脉支架置入术和重组疗法等标靶治疗方案需求的可能性。该倡议旨在促进预防保健，并支持更广泛地获得基本血管医疗服务。

美国门诊手术中心 (ASC) 和办公室实验室 (OBL) 的激增大大促进了血管介入手术量的增加，包括主髂动脉阻塞性疾病。这些中心为传统医院设施提供了一种经济高效且方便的替代方案，可迅速治疗患者、降低开销并允许患者和医生灵活安排时间。因此，髂动脉介入治疗，如球囊血管成形术、置入术和动脉粥状硬化动脉粥状硬化斑块切除术，越来越多地在 ASC 和 OBL 中进行，特别是对于患有早期到中期疾病的患者。这些微创手术通常可以在门诊进行，非常适合这些中心，因为缩短恢復时间和降低手术风险是这些中心的首要任务。优惠的报销政策也支持向此类中心的转变，使它们成为护理提供者和付款人的首选地点。

目录

第一章 分析方法与范围

第二章执行摘要

第三章美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章美国主动脉髂动脉阻塞性疾病（髂动脉疾病）治疗市场：依设备类型估计与趋势分析

  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场（依仪表板、设备类型）
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：按设备类型分類的容量分析
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场收益（以设备类型）
  • 血管内装置
    • 球囊血管成形术装置
    • 动脉粥状硬化斑块切除系统
    • 支架
  • 手术设备

第五章美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：依程序的估计与趋势分析

  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场，仪表板，依程序
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：按治疗程序进行的数量分析
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场收益（依治疗方式）
  • 血管内手术
    • 球囊血管成形术
    • 初次支架置入术
    • 吻合支架
    • 覆膜血管支架
    • 主动脉腔内修復术（EVAR）
  • 混合手术
  • 外科手术

第六章。美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场：按最终用途的估计和趋势分析

  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场（依最终用途划分）
  • 美国主动脉髂动脉阻塞性疾病（髂动脉疾病）治疗市场：依最终用途分類的销售分析
  • 美国主髂动脉阻塞性疾病（髂动脉疾病）治疗市场（按收益和最终用途）
  • 医院
  • 门诊设施
  • 其他的

第七章 竞争态势

  • 主要製造商的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要企业市场占有率分析（2024年）
  • 公司简介
    • BD
    • Abbott
    • Boston Scientific Corporation
    • WL Gore &Associates, Inc.
    • Medtronic
    • Cook
    • Terumo Corporation
    • Getinge AB
Product Code: GVR-4-68040-614-6

Market Size & Trends:

The U.S. aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 716.6 million in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030. Increasing PAD incidence, rising government initiatives, and technological advancements drive market growth. For instance, in November 2024, Philips recently launched the THOR IDE clinical trial in the U.S. to evaluate a novel hybrid catheter system that combines laser atherectomy and intravascular lithotripsy.

The device is designed to treat severely calcified lesions commonly found in PAD and aorto-iliac disease. The first successful patient procedure, conducted at the Cardiovascular Institute of the South in Louisiana, demonstrates the potential for this device to streamline complex interventions and improve procedural outcomes. Increasing government initiatives drive market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs.

Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, which are critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

The proliferation of ambulatory surgical centers (ASCs) and office-based labs (OBLs) across the U.S. significantly contributes to the growth in procedural volumes for vascular interventions, including those for aorto-iliac occlusive disease. These facilities offer a cost-effective and convenient alternative to traditional hospital settings, enabling quicker patient turnaround, reduced overhead costs, and enhanced scheduling flexibility for both patients and physicians. As a result, iliac artery interventions-such as balloon angioplasty, stenting, and atherectomy are increasingly being performed in ASCs and OBLs, especially for patients presenting with early to moderate stages of the disease. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.

U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use:

  • Device Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Endovascular Devices
    • Balloon Angioplasty Devices
    • Atherectomy Systems
    • Stents
    • Self-Expanding Stents
    • Balloon-Expandable Stents
    • Covered Stent Grafts
    • Bifurcated Aortic Stent Grafts
  • Surgical Devices
  • Procedure Outlook (Revenue, USD Million, 2018 - 2030)
  • Endovascular Procedures
    • Balloon Angioplasty
    • Primary Stenting
    • Kissing Stents
    • Covered Stent Grafts
    • Endovascular Aortic Repair (EVAR)
  • Hybrid Procedures
  • Open Surgical Procedures
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Outpatient Facilities
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Device Type
    • 1.2.2. Procedure
    • 1.2.3. End Use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Volume price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Device Type outlook
    • 2.2.2. Procedure outlook
    • 2.2.3. End Use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of peripheral artery disease (PAD)
      • 3.2.1.2. Advancements in endovascular technologies
      • 3.2.1.3. Shift towards in minimally invasive procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product recalls
      • 3.2.2.2. Clinical complexity and procedural risks
  • 3.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis

  • 4.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
  • 4.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
  • 4.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Device Type, Revenue
  • 4.4. Endovascular Devices
    • 4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.2. Balloon Angioplasty Devices
      • 4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.3. Atherectomy Systems
      • 4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4. Stents
      • 4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.2. Self-expanding Stents
        • 4.4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.3. Balloon-expandable Stents
        • 4.4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.4. Covered stent grafts
        • 4.4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.4.5. Bifurcated aortic stent grafts
        • 4.4.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.5. Surgical Devices
    • 4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis

  • 5.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
  • 5.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
  • 5.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Procedure, Revenue
  • 5.4. Endovascular Procedures
    • 5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.2. Balloon Angioplasty
      • 5.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Primary Stenting
      • 5.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.4. Kissing Stents
      • 5.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.5. Covered Stent Grafts
      • 5.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.6. Endovascular Aortic Repair (EVAR)
      • 5.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Hybrid Procedures
    • 5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Surgical Procedures
    • 5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
  • 6.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
  • 6.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by End Use, Revenue
  • 6.4. Hospitals
    • 6.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Outpatient Facilities
    • 6.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. BD
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Abbott
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Boston Scientific Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. W. L. Gore & Associates, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Medtronic
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Cook
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Terumo Corporation
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Getinge AB
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of secondary sources
  • Table 3 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by device type, 2018 - 2030 (USD Million)
  • Table 4 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by procedure, 2018 - 2030 (USD Million)
  • Table 5 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new services
  • Table 12 Key companies undergoing partnerships
  • Table 13 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. aorto-iliac occlusive disease (iliac disease) treatment market segmentation
  • Fig. 7 Market snapshot, 2024
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market driver relevance analysis (current & future impact)
  • Fig. 10 Market restraint relevance analysis (current & future impact)
  • Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Outlook Key Takeaways
  • Fig. 14 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Movement Analysis
  • Fig. 15 Endovascular devices market, 2018 - 2030 (USD Million)
  • Fig. 16 Balloon angioplasty devices market, 2018 - 2030 (USD Million)
  • Fig. 17 Atherectomy systems market, 2018 - 2030 (USD Million)
  • Fig. 18 Stents market, 2018 - 2030 (USD Million)
  • Fig. 19 Self-expanding stents market, 2018 - 2030 (USD Million)
  • Fig. 20 Balloon-expandable stents market, 2018 - 2030 (USD Million)
  • Fig. 21 Covered stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 22 Bifurcated aortic stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 23 Surgical devices market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure outlook key takeaways
  • Fig. 25 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure movement analysis
  • Fig. 26 Endovascular procedures market, 2018 - 2030 (USD Million)
  • Fig. 27 Balloon angioplasty market, 2018 - 2030 (USD Million)
  • Fig. 28 Primary stenting market, 2018 - 2030 (USD Million)
  • Fig. 29 Kissing stents market, 2018 - 2030 (USD Million)
  • Fig. 30 Covered stent grafts market, 2018 - 2030 (USD Million)
  • Fig. 31 Endovascular aortic repair (EVAR) market, 2018 - 2030 (USD Million)
  • Fig. 32 Hybrid procedures market, 2018 - 2030 (USD Million)
  • Fig. 33 Open surgical procedures market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use outlook key takeaways
  • Fig. 35 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use movement analysis
  • Fig. 36 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 37 Outpatient facilities market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Strategy framework